Factors predicting the 1-year outcome of collagenase treatment for Dupuytren’s disease

Scheibler, Anne-Gita; Marks, Miriam; Hensler, Stefanie; Herren, Daniel; Calcagni, Maurizio

doi:10.1007/s00402-019-03120-y

Cited by 5 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…85% of the patients in the same study had a significant improvement of the contracture of at least 50%. The CORD II study as well as further clinical studies confirmed the efficacy and safety of this investigational treatment option [13–19, 4, 20–22].…”

Section: Introductionmentioning

confidence: 73%

See 1 more Smart Citation

Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register

Arora

Angermann

Paul

et al. 2019

Arch Orthop Trauma Surg

View full text Add to dashboard Cite

Introduction Since March 2011, the microbial collagenase of Clostridium histolyticum ( Xiapex®, Swedish Orphan Biovitrum AB, Stockholm, Sweden) has become available in the European Union for treatment of Dupuytren’s disease. The purpose of this study was to evaluate potential safety risks of Xiapex® and to contribute to a better understanding for its use. Methods A prospective, non-interventional, observational study using Xiapex® for Dupuytren’s disease named XIANIS was conducted between 1.10.2011 and 01.10.2017. Treatment was conducted in accordance to the manufacturer information. Patients were invited for follow-up after 1 week, 1 month, 3 months and 1 year. Demographic data, treatment data, pain levels, anaesthetic application during passive manipulation, subjective function improvement, subjective satisfaction and adverse events were recorded. Results 788 patients with 814 treatments were included who suffered from Dupuytren’s contracture for a mean of 64 months. The metacarpophalangeal joint was affected in 57% of cases and the PIP joint in 40.8% with a mean contracture of 39° and 56°, respectively. A change in the contracture down to 0°–5° was reported in 66.5% of cases, while 25.5% achieved a partial improvement. The pain during the injection was rated 4.5 and 3.3 during passive manipulation. Adverse events were reported in the majority of treated patients with skin tears being one main common event (26%). Further adverse outcomes were bleeding/hematoma, joint swelling, injection-site swelling, pressure sensitivity, erythema, injection-site pain, peripheral edema, blood blisters, blisters, painless lymphadenopathy, painful lymphadenopathy, axillary pain, arthralgia and sensory abnormality. There were no reported tendon ruptures, anaphylactic reactions or ligament injuries. On 1-year follow-up, 29% showed an increased contracture of a mean of 24° with the need for surgical treatment in 2% of patients. 74% of patients were very satisfied and 72% showed a high functional improvement. Conclusion The injectable collagenase Clostridium histolyticum (Xiapex®) proved to be effective and safe in patients with Dupuytren’s disease. Minor adverse events disappeared within 30 days and the need for surgical treatment within 1 year was very low (2%). No major complications or rare side effects were seen in this prospective observational study.

show abstract

Section: Introductionmentioning

confidence: 73%

“…Alcohol, nicotine and work with vibrating machines seem to have a negative influence on the course of the disease [2]. There is no known cure for this disorder [3, 4]. Therefore, treatment options target primarily on restoring the normal function of the hand by disrupting or removing the Dupuytren’s cord but not resolving the disease.…”

Section: Introductionmentioning

confidence: 99%

Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register

Arora

Angermann

Paul

et al. 2019

Arch Orthop Trauma Surg

View full text Add to dashboard Cite

show abstract

“… 14 They have shown validity and reliability in patients with DD but are currently only applied to evaluate treatment results. 15 The use of these PROMs to monitor the disease course of patients with DD remotely has not been explored.…”

mentioning

confidence: 99%

Patient-Perceived Hand Function Can Predict Treatment for Dupuytren Disease

Berge¹,

Blom²,

Werker³

et al. 2023

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Background: Web-based patient-reported outcome measures (PROMs) could help surgeons remotely assess the need for examination and subsequent treatment of patients with Dupuytren disease (DD). The authors studied whether the Unité Rhumatologique des Affections de la Main (URAM) and the Michigan Hand Questionnaire (MHQ) could predict DD treatment. Methods: In this prospective cohort study, the authors compared MHQ and URAM scores of treated patients with those of untreated patients. For the treatment group, the authors selected a score closest to 1 year before treatment. For controls, the authors randomly selected a score. The authors also tested the predictive value of a 1-year change score between 15 months and 6 weeks before treatment. The primary outcome measure was DD treatment. The predictive value was determined using the area under the curve (AUC). An AUC greater than 0.70 was considered good predictive ability; 0.70 to 0.50, poor predictive ability; and less than 0.50, no predictive ability. Results: The authors included 141 patients for the MHQ analysis and 145 patients for the URAM analysis. The AUC of the MHQ and URAM scores measured 1 year before treatment were 0.80 (95% CI, 0.71 to 0.88) and 0.75 (95% CI, 0.68 to 0.82), respectively. The 1-year change score resulted in an AUC less than 0.60 for both questionnaires. Conclusions: The results show that both the MHQ and URAM score measured around 1 year before treatment can predict treatment for DD. If future studies show that telemonitoring of patients with DD with PROMs is also cost-effective, web-based PROMs could optimize patient care and effectiveness of DD treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

show abstract

Explaining Personalized Activity Limitations in Patients With Hand and Wrist Disorders: Insights from Sociodemographic, Clinical, and Mindset Characteristics

Lachman,

van Kooij,

Slijper

et al. 2024

Archives of Physical Medicine and Rehabilitation

View full text Add to dashboard Cite

Factors predicting the 1-year outcome of collagenase treatment for Dupuytren’s disease

Cited by 5 publications

References 26 publications

Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register

Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren’s disease in 788 patients: the Austrian register

Patient-Perceived Hand Function Can Predict Treatment for Dupuytren Disease

Explaining Personalized Activity Limitations in Patients With Hand and Wrist Disorders: Insights from Sociodemographic, Clinical, and Mindset Characteristics

Contact Info

Product

Resources

About